SEARCH · Search PubMed

Results for “PROCAINE AMIDE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources

PubMed1952

[Hazards in procaine amide therapy].

Explore the source record for details and available documents.

Procainamide↗

PubMed1950

NEW and nonofficial remedies: procaine amide hydrochloride.

Explore the source record for details and available documents.

Procainamide↗

PubMedDate not supplied

The effect of Craviten, a new antiarrhythmic drug, its 2R, 2'R isomer, quinidine and procaine amide on human platelet aggregation.

Among the optical isomers of N, N'-dimethyl-N, N'-bis[1-(3', 4', 5-trimethoxybenzoyloxy)-butyl-2]-ethylenediamine dihydrochloride only the isomer with the (2S, 2'S) configuration (Craviten) in a concentration of 0.2 microgram/ml inhibits the ADP-induced aggregation of human platelets. The (2R, 2'R) isomer and quinidine exert a similar effect but only in a concentration ten times higher. Procaine amide (2 micrograms/ml) has an opposite effect, stimulating human platelet aggregation.

Adenosine Diphosphate↗

PubMed1967

Ventricular arrhythmias and K+ transfer during myocardial ischemia and intervention with procaine amide, insulin, or glucose solution.

To assess the relation of ventricular arrhythmias to myocardial K(+) movement during ischemia, we placed an electrode catheter in the left anterior descending coronary artery for thrombus production in intact anesthetized dogs. (85)Kr injections distal to the thrombus permitted serial coronary blood flow measurements. Animals of Group I with a moderate flow reduction exhibited no arrhythmia or myocardial egress of K(+). In Group II, marked flow reduction was accompanied by an injury potential and loss of K(+) from the ischemic site, before and during ventricular tachycardia. Therapeutic interventions were performed in animals having the same degree of ischemia as Group II. Systemic procaine amide in Group III interrupted the tachycardia and egress of K(+), despite persistent ischemia. Group IV did not respond to intracoronary insulin with K(+) uptake, as did normal dogs, and progressed to fibrillation. During the production of hyperglycemia in Group V, myocardial loss of K(+) ceased with maintenance of sinus rhythm. Hemodynamic factors did not appear to have a major role in the genesis of the arrhythmia.Since intracoronary infusion of K(+) in normal dogs similarly altered repolarization and produced fibrillation, it would appear that during ischemia egress of K(+) before development of the arrhythmia indicates a major role of the ion in pathogenesis. This view is supported by the myocardial loss of K(+) and arrhythmia induced in normal dogs by strophanthidin and by the fact that pharmacologic regulation of K(+) loss is associated with correction of the arrhythmia, despite persistence of low blood flow.

Animals↗

PubMedDate not supplied